# Medication Intelligence Phase 15 — Authoritative Source Acquisition, Tier-1 Knowledge Completion, and Wave 1 Remediation

**Certification ID:** `MEDUI.MEDICATION_INTELLIGENCE_PHASE_15_AUTHORITATIVE_SOURCE_ACQUISITION_TIER1_KNOWLEDGE_COMPLETION_AND_WAVE1_REMEDIATION`

**Final decision (live certifier):** truthfully emitted — typically `MEDICATION_INTELLIGENCE_PHASE_15_CERTIFIED_WITH_GOVERNED_DEFERRALS` when Tier-1 positive gaps remain openly deferred without fabricating facts. Complete Tier-1 knowledge would yield `MEDICATION_INTELLIGENCE_PHASE_15_CERTIFIED`.

| Part | Status | Doc |
|------|--------|-----|
| Part 1 — Governance foundation | Complete | this document (foundation sections) |
| Part 2A — Remediation / DB | Complete | migration + remediation services |
| Part 2B — Operational API/UI/CLI | Complete | [`medication-intelligence-phase-15-part2b-operational-api-ui-cli.md`](./medication-intelligence-phase-15-part2b-operational-api-ui-cli.md) |
| Part 2C — Execution / requalification / certification | Complete | [`medication-intelligence-phase-15-part2c-execution-certification.md`](./medication-intelligence-phase-15-part2c-execution-certification.md) |

---

## Mission

Transform Wave 1 medication families from **Qualified With Gaps** into **Qualified With Complete Authoritative Knowledge** using legally governed, authoritative medication references — without changing how clinicians order or administer medications.

Phase 15 **SHALL NOT** expand beyond Wave 1. Acetaminophen remains **IDENTITY_BLOCKED**.

## Constitutional rules (permanent)

1. Medication Intelligence governs knowledge — never patient care
2. Knowledge completion never delays treatment
3. Knowledge approval never blocks ordering, administration, dispensing, or emergency treatment
4. Tier-1 evidence governs knowledge — never patient workflow
5. Knowledge quality ≠ production activation
6. Completion ≠ clinical decision support
7. Shadow ≠ production
8. Medication Intelligence remains advisory

## Live baseline (from certified Phase 14B — calculated, not hard-coded)

Query sources: `MedicationKnowledgeApprovalWaveItem`, `MedicationShadowSnapshot`, `MedicationShadowEvaluationBatch` (`EM_WAVE1_SYNTHETIC_SHADOW_VALIDATION_V1`), `MedicationShadowGapLink`.

| Metric | Live value (Part 1 capture) |
|--------|------------------------------|
| Wave1Families / ApprovedForShadow | 8 / 8 |
| ShadowSnapshots / ShadowExecuted | 8 / 8 |
| Synthetic readiness | `QUALIFIED_WITH_GAPS` |
| CriticalMisses / UnexpectedFindings | 0 / 0 |
| Open knowledge gaps (Tier-1 positive documentation) | 8 |
| ClinicalActivations / ProviderAlerts / OrderBlocks | 0 / 0 / 0 |
| Acetaminophen in Wave 1 | NO (identity-blocked) |

Artifact: `apps/api/prisma/medications/audit-summaries/medication-phase15-part1-foundation-baseline.json`

## Wave 1 families (only)

Ibuprofen, Ondansetron, Famotidine, Pantoprazole, Dexamethasone, Prednisone, Cetirizine, Ipratropium.

## Pre-implementation reuse audit

| Phase | Reuse (do not recreate) |
|-------|-------------------------|
| 1–2 | Canonical identity, concepts, products, packages, routes |
| 3–7 | Knowledge architecture, clinical/safety domains |
| 8 / 14A | Evidence registration, provenance links, completeness scores, source tiers |
| 9 | Safety knowledge (interactions, duplicate therapy, cross-reactivity) |
| 10 | Evaluation engine — **no mode changes** (`DISABLED` \| `SHADOW` only) |
| 11 | Coverage analytics, `MedicationKnowledgeGap` / `MedicationIdentityGap` |
| 12 | Population batch / CLI / APIs / UI |
| 13 | Identity resolution, approval wave, shadow framework |
| 14B | Expert review, quality, snapshots, synthetic validation, gap links, reporting |

Nothing in Phase 15 replaces these systems.

## Architecture (unchanged)

```
Canonical Medication → Evidence Sources → Knowledge Domains → Expert Review
→ Shadow Qualification → Synthetic Validation → Knowledge Completion
→ Production Readiness Assessment
```

## Part 1 deliverables

| Area | Action |
|------|--------|
| Shared | `medicationAuthoritativeSourceAcquisitionGovernance.ts` (+ tests) |
| Lifecycle extension | `AUTHORITATIVE_SOURCE_CONFIRMED` (shared enum; Part 2 wires persistence) |
| Gap classification | Map Phase 14B gap types → remediation categories; Tier-1 positives require authoritative sources |
| Docs / roadmap | This document + roadmap Part 1 / Part 2 split |
| Baseline audit JSON | Live metrics capture |

## Part 2C outcome note

Live repository sources remain institutional (Tier-5). Part 2C therefore **defers** the eight Wave 1 Tier-1 positive knowledge gaps with full audit, recalculates quality, reuses immutable shadow snapshots (no content change), reports prior synthetic CERTIFIED batch results, and certifies with governed deferrals. No fabricated Tier-1 clinical facts.

## Knowledge completion philosophy

- Complete only where authoritative evidence supports it
- Unsupported domains remain **DEFERRED**
- Never infer, hallucinate, or synthesize from weak references
- Never fabricate Tier-1 clinical facts to satisfy completeness metrics

## Source philosophy

Distinguish authority, scope, version, licensing status, and review status.
Lower-tier catalog presence alone must not promote content to authoritative completion.
Do not embed copyrighted source content in the repository.

## Safety boundaries

| Control | Status |
|---------|--------|
| Provider alerts / order blocking / CDS | OFF |
| Clinical activation | OFF |
| Knowledge controls patient care | NO |
| Ordering / MAR / reconciliation / dispensing / billing | UNCHANGED |
| Wave expansion / acetaminophen resolution | FORBIDDEN |

## Shared constants

- Program key: `EM_WAVE1_AUTHORITATIVE_SOURCE_REMEDIATION_V1`
- Package: `@medora/shared` → `medicationAuthoritativeSourceAcquisitionGovernance`

## Phase boundary

Phase 15 is complete when Parts 1–2C are implemented, live remediation executed, and the certifier emits a truthful decision. Patient-care workflows remain unchanged.

**Next (do not begin in Phase 15):** `MEDICATION_INTELLIGENCE_PHASE_16_EMERGENCY_MEDICINE_FAMILY_EXPANSION_AND_CONTROLLED_KNOWLEDGE_POPULATION`
